SIT1 transporter as a potential novel target in treatment of COVID-19
, S., Biomolecular Concepts, doi:10.1515/bmc-2021-0017 (Review)
, SIT1 transporter as a potential novel target in treatment of COVID-19, , S., Biomolecular Concepts, doi:10.1515/bmc-2021-0017 (Review)
Review of the potential connections between SLC6A20/SIT1, ACE2, Type 2 Diabetes, and COVID-19 severity. This provides another potential mechanism of action for ivermectin as a partial agonist of glycine-gated chloride channels, interfering with cytokine storm by inducing activation of glycine receptors. Author recommends investigating targeting of the SIT1 transporter and glycine levels in the treatment of COVID-19, particularly for severe cases associated with hyperglycemia, inflammation, and T2D.
Semiz et al., 30 Dec 2021, peer-reviewed, 1 author.
Abstract: BioMol Concepts 2021; 12: 156–163
Open Access
Communication
Sabina Semiz*
SIT1 transporter as a potential novel target in
treatment of COVID-19
https://doi.org/10.1515/bmc-2021-0017
received October 31, 2021; accepted November 29, 2021.
Loading..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.